Catalent, Inc. (NYSE:CTLT) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Catalent, Inc. (NYSE:CTLT) have received a consensus rating of “Hold” from the eight ratings firms that are covering the firm, Marketbeat reports. Eight investment analysts have rated the stock with a hold rating. The average 12-month target price among brokerages that have covered the stock in the last year is $59.83.

A number of analysts have commented on CTLT shares. Baird R W lowered shares of Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. William Blair reiterated a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Robert W. Baird restated a “neutral” rating and set a $63.50 target price on shares of Catalent in a report on Tuesday, September 24th. Barclays upped their price target on Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research note on Friday, June 28th. Finally, Royal Bank of Canada restated a “sector perform” rating and set a $63.50 price objective on shares of Catalent in a report on Thursday, July 11th.

Insider Transactions at Catalent

In other Catalent news, insider Ricky Hopson sold 662 shares of the firm’s stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $59.56, for a total value of $39,428.72. Following the completion of the transaction, the insider now directly owns 29,974 shares in the company, valued at $1,785,251.44. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, insider Ricky Hopson sold 662 shares of Catalent stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $59.56, for a total value of $39,428.72. Following the completion of the transaction, the insider now owns 29,974 shares of the company’s stock, valued at $1,785,251.44. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider David Mcerlane sold 1,994 shares of the business’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the transaction, the insider now owns 36,304 shares in the company, valued at $2,177,150.88. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 12,410 shares of company stock valued at $732,680 over the last 90 days. 0.31% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CTLT. Thurston Springer Miller Herd & Titak Inc. bought a new position in Catalent during the second quarter worth $42,000. Mather Group LLC. bought a new stake in shares of Catalent during the 1st quarter worth about $52,000. Longfellow Investment Management Co. LLC grew its stake in Catalent by 45.7% in the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after buying an additional 305 shares during the last quarter. GAMMA Investing LLC raised its holdings in Catalent by 25.9% in the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after acquiring an additional 212 shares during the period. Finally, Sound Income Strategies LLC boosted its holdings in shares of Catalent by 4,466.7% during the first quarter. Sound Income Strategies LLC now owns 1,370 shares of the company’s stock worth $77,000 after acquiring an additional 1,340 shares during the period.

Catalent Stock Down 0.3 %

NYSE CTLT opened at $60.09 on Friday. The stock has a market capitalization of $10.88 billion, a P/E ratio of -9.85, a price-to-earnings-growth ratio of 2.14 and a beta of 1.15. Catalent has a 52 week low of $31.80 and a 52 week high of $61.20. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.96 and a current ratio of 2.52. The stock has a fifty day moving average of $60.11 and a 200-day moving average of $57.75.

Catalent (NYSE:CTLT) last announced its quarterly earnings data on Thursday, August 29th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.13. The firm had revenue of $1.30 billion during the quarter, compared to analysts’ expectations of $1.23 billion. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. On average, equities research analysts forecast that Catalent will post 0.95 EPS for the current year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.